Short profile
Name: **Auristone**

Medical field	Cancer/Oncology
Product type	Advanced technologies (AI and deep learning, VR and simulation, novel materials
Growth stage	Positioning for scale
Team	13 people

Description of product:

Based on RNA-Seq on FFPE slides, we report epigenomic information such as gene fusion, gene expression, and alternate isoform readouts and provide clinically validated algorithmic outputs that provide likelihood of response to immunotherapy and to treatment regimes in successfully concluded clinical trials. We can provide an epigenomic report (RNA-Seq based) or an integrated genomic/epigenomic report (DNA-Seq and RNA-Seq based), with the latter comprising standard genomic readouts such as mutation and copy number variant calls.

Desired project goal: *Please also elaborate on the primary outcome*

Test bedding of EPI-Call™ (comprehensive molecular profiling test for therapy selection in late-stage cancer patients) in Charité for clinical (trial) use:

- EPI-Call™ reports epigenomic information that can be used to guide therapy selection for late stage cancer patients.
- The epigenomic information provided for by EPI-Call™ may also be used in a clinical trial setting for patient recruitment and/or biomarker discovery.
- In particular, EPI-Call™ can be deployed for use in GI cancers.

Desired project type: *Please also elaborate on the following points, if applicable: population, intervention, study design etc.*

Test bedding and validation.

chewjingming@auristone.com

+65 8338 4555

www.auristone.com

DR. HANA HASTOR, Medical Advisor CSC (CRU)
hana.hastor@bih-charite.de